| Elranatamab studied in …STUDIED_INderived47 of 47show fewer |
|---|
| → studied in | NCT06421675Phase 2 · recruiting Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997081Phase 2 · recruiting ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07382739Phase 2 · recruiting A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06832865Phase 2 · recruiting ELISA in Relapsed/Refractory MM · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06215118Phase 1 · active not recruiting A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637578Phase 2 · recruiting A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05927571Phase 1 · recruiting A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06183489Phase 2 · active not recruiting Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06988488Phase 1/Phase 2 · recruiting A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06138275Phase 2 · recruiting Elranatamab in R/R Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020236Phase 3 · recruiting A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152575Phase 3 · recruiting MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06106945Phase 1/Phase 2 · recruiting AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06569147Phase 1/Phase 2 · recruiting Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis · 47 trials list this drug (38 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05675449Phase 1 · active not recruiting A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07280013Phase 1 · recruiting A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918002Phase 3 · recruiting Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06207799Phase 2 · recruiting Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855121recruiting The Norwegian Immunotherapy in Multiple Myeloma Study · 47 trials list this drug (38 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06121843Phase 1 · recruiting A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06057402Phase 4 · recruiting Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 47 trials list this drug (38 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07247097Phase 2 · not yet recruiting ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07454382Phase 2 · recruiting A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07647432Phase 2/Phase 3 · not yet recruiting HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV · 47 trials list this drug (38 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282978Phase 2 · active not recruiting Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06974786Phase 2 · recruiting Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04649359Phase 2 · active not recruiting MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799026Phase 1 · recruiting A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05317416Phase 3 · active not recruiting Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06711705Phase 2 · recruiting Elranatamab in Relapsed/Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014412Phase 2 · completed A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015542Phase 2 · recruiting Self-administration of Subcutaneous Elranatamab in the Patients' Homes. · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07320326not yet recruiting ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab · 47 trials list this drug (38 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06645678Phase 1/Phase 2 · recruiting Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06947083Phase 2 · recruiting Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06581848active not recruiting Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504524completed A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06592222completed A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06931704Phase 2 · not yet recruiting Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238311no longer available Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135) · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05932290completed A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04798586Phase 1 · completed MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05462639no longer available Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05565391completed A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma · 47 trials list this drug (38 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |